Disease · EFO_1001941
bronchioloalveolar carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bronchioloalveolar carcinoma. Diseases, record EFO_1001941. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001941
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
BAC, Bronchioalveolar Adenocarcinoma of Lung, Bronchioalveolar Lung Carcinoma, Bronchiolo-Alveolar Carcinoma of Lung, Bronchiolo-Alveolar Lung Carcinoma, Bronchioloalveolar Adenocarcinoma of Lung, bronchioalveolar adenocarcinoma of the lung, bronchiolo-alveolar carcinoma of the lung, bronchioloalveolar adenocarcinoma of the lung, bronchioloalveolar lung adenocarcinoma, bronchoalveolar adenocarcinoma, carcinoma, bronchioloalveolar, malignant, minimally invasive lung adenocarcinoma
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERLOTINIB | CHEMBL553 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GEFITINIB | CHEMBL939 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LAPATINIB | CHEMBL554 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEMETREXED DISODIUM | CHEMBL2360464 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets67
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 1 | Serine/threonine-protein kinase B-raf inhibitor | Phase 2 | https://conductscience.org/library/genes/673 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 1 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 1 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| GART | Trifunctional purine biosynthetic protein adenosine-3 | 1 | GAR transformylase inhibitor | Phase 2 | https://conductscience.org/library/genes/2618 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
1 to 10 of 67
See all 67 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase 2 | 131 | 2010-01-06 | Lung Cancer, Non-Small Cell | LAPATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00103207 | Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer | Phase 2 | 72 | 2013-01-04 | Lung Cancer | CETUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00265785 | S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Phase 2 | 27 | 2012-11-01 | Lung Cancer | PEMETREXED DISODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | Phase 2 | 133 | Adenocarcinoma, Bronchiolo-Alveolar | CARBOPLATIN, ERLOTINIB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Phase 2 | 90 | Bronchoalveolar Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | GEFITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00002969 | S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Phase 2 | 60 | Lung Cancer | PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00456716 | Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma | Phase 2 | 5 | Lung Cancer | SORAFENIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features | Phase 2 | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar | BORTEZOMIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Lapatinib 1500 mg QD vs Lapatinib 500 mg BID: serious adverse events | 15 of 65 | 17 of 66 | 131 | NCT00073008 |
Source Trial comparisons
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001941
GET https://conductscience.org/api/diseases/v1/EFO_1001941/targets?page=2